Johnson & Johnson (JNJ) Drugs Lift Guidance, but Is 23 Times Earnings Fair?

Johnson & Johnson (NYSE:JNJ) raised its 2026 forecast earlier this month. It now expects full-year sales of about $101.2 billion at the midpoint, a little higher than its July outlook, and slightly higher adjusted earnings per share too. The company is one of the 10 No-Brainer Stocks to Buy Now. But the quarter behind that […]